SCHEMBL1367551

SCHEMBL1367551

COc1ccc2cc(C(=O)c3cc4ccc(OC)cc4[nH]c3=O)c(=O)[nH]c2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.62
ALDH1A1 P00352 4/20 0.62
POLB P06746 1/20 0.62
GAA P10253 1/20 0.62
FLT3 P36888 5/20 0.57
PDGFRB P09619 3/20 0.57
PDGFRA P16234 2/20 0.57
HSD17B10 Q99714 7/20 0.53
TP53 P04637 1/20 0.53
MAPT P10636 1/20 0.53
ALOX15 P16050 1/20 0.53
PADI4 Q9UM07 1/20 0.52
TSHR P16473 3/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
LMNA P02545 1/20 0.51
RECQL P46063 1/20 0.51
CA2 P00918 1/20 0.50
CYP1A2 P05177 1/20 0.50
HPGD P15428 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31222326 0.89 KDM4E (0.78) KDM4EALDH1A1POLBGAAFLT3
SCHEMBL24373426 0.88 KDM4E (0.59) KDM4EALDH1A1POLBGAAFLT3
SCHEMBL5475986 0.84 KDM4E (0.56) KDM4EALDH1A1POLBGAAFLT3
SCHEMBL31423219 0.83 KDM4E (0.58) KDM4EALDH1A1POLBGAAHSD17B10
SCHEMBL433980 0.79 BRD4 (0.56) KDM4EALDH1A1POLBGAAFLT3
SCHEMBL1072455 0.78 CA2 (0.56) KDM4EALDH1A1POLBGAAFLT3
SCHEMBL8220830 0.78 CA2 (0.53) KDM4EALDH1A1POLBGAAFLT3
SCHEMBL4377723 0.78 CA2 (0.53) KDM4EALDH1A1POLBGAAFLT3
SCHEMBL31222313 0.77 KDM4E (1.00) KDM4EALDH1A1POLBGAAFLT3
SCHEMBL31222308 0.77 KDM4E (1.00) KDM4EALDH1A1POLBGAAFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US claimed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO claimed
US-8067461-B2 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-11-29 US disclosed
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US disclosed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof NQO2, NQO1, HCCS KDM4E 2293/4885ALDH1A1 617/4885POLB 2722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.